Updated from 8:15 a.m. ET with the addition of Mark Thompson of Concordia International.
Elizabeth Holmes of Theranos is the Worst Biopharma CEO of 2016.
Even with a crowded field of awful CEO candidates this year, no one else in health care -- or any industry for that matter -- could touch Holmes' loathsome mix of arrogance, incompetence and duplicity.
Holmes is the first female CEO to be singled out for this (dis)honor since I started highlighting biotech executive misbehavior in 2009. Theranos is a privately held blood-testing firm, which would normally put Holmes beyond the reach of my focus on executives running publicly traded biotech and drug companies.
Exceptions, however, needed to be made. Holmes' performance as CEO of Theranos was so irredeemably atrocious that it couldn't be contained within a single calendar year.
The deeply sourced investigative reporting of Wall Street Journal reporter John Carreyrou revealed Theranos' finger-prick blood-testing technology to be a sham that put patients at risk. Holmes' compelling backstory -- Stanford University dropout who turned a simple idea into a billion-dollar Silicon Valley startup -- was a myth. Unicorns really are make-believe.
Let's take a look at the other super-bad CEOs of 2016.